AR092858A1 - Procedimiento para una sintesis mejorada de opioide - Google Patents

Procedimiento para una sintesis mejorada de opioide

Info

Publication number
AR092858A1
AR092858A1 ARP130102525A ARP130102525A AR092858A1 AR 092858 A1 AR092858 A1 AR 092858A1 AR P130102525 A ARP130102525 A AR P130102525A AR P130102525 A ARP130102525 A AR P130102525A AR 092858 A1 AR092858 A1 AR 092858A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
cycloalkyl
compositions
compounds
Prior art date
Application number
ARP130102525A
Other languages
English (en)
Spanish (es)
Original Assignee
Rhodes Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodes Tech filed Critical Rhodes Tech
Publication of AR092858A1 publication Critical patent/AR092858A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
ARP130102525A 2012-07-16 2013-07-15 Procedimiento para una sintesis mejorada de opioide AR092858A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672260P 2012-07-16 2012-07-16
US201261741480P 2012-07-19 2012-07-19
US201361762637P 2013-02-08 2013-02-08

Publications (1)

Publication Number Publication Date
AR092858A1 true AR092858A1 (es) 2015-05-06

Family

ID=48916127

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102525A AR092858A1 (es) 2012-07-16 2013-07-15 Procedimiento para una sintesis mejorada de opioide

Country Status (21)

Country Link
US (3) US10316042B2 (OSRAM)
EP (1) EP2872516B1 (OSRAM)
JP (1) JP6236447B2 (OSRAM)
KR (1) KR101946103B1 (OSRAM)
CN (1) CN104470928B (OSRAM)
AR (1) AR092858A1 (OSRAM)
AU (2) AU2013291725B2 (OSRAM)
BR (1) BR112015000944A2 (OSRAM)
CA (2) CA2974010A1 (OSRAM)
CO (1) CO7180188A2 (OSRAM)
EA (1) EA028092B1 (OSRAM)
ES (1) ES2647949T3 (OSRAM)
IL (1) IL236710B (OSRAM)
IN (1) IN2015DN01165A (OSRAM)
MX (1) MX363610B (OSRAM)
NZ (1) NZ628699A (OSRAM)
PH (1) PH12015500089A1 (OSRAM)
SG (1) SG11201407988UA (OSRAM)
TW (2) TWI643860B (OSRAM)
UA (1) UA117225C2 (OSRAM)
WO (1) WO2014013313A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5923827B2 (ja) * 1981-12-16 1984-06-05 フエザ−安全剃刀株式会社 安全かみそり刃
KR101946104B1 (ko) 2012-07-16 2019-02-08 로드스 테크놀로지즈 개선된 오피오이드 합성을 위한 방법
CN110172063A (zh) * 2013-08-02 2019-08-27 庄信万丰股份有限公司 用于制备氢羟吗啡酮的方法
MX379406B (es) * 2014-01-15 2025-03-11 Rhodes Tech Proceso para la síntesis mejorada de oximorfona.
JP2017502991A (ja) 2014-01-15 2017-01-26 ローズ テクノロジーズ 改良されたオキシコドン合成のための方法
CA2954600A1 (en) * 2014-07-09 2016-01-14 Rhodes Technologies Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions
US20160052932A1 (en) 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US20160340362A1 (en) * 2015-05-20 2016-11-24 Noramco, Inc. Process For The Preparation Of Oxymorphone Freebase
EP3252055B1 (en) 2016-05-31 2018-09-19 Alcaliber Investigacion Desarrollo e Innovacion SLU Process for obtaining 3,14-diacetyloxymorphone from oripavine
US10935314B2 (en) * 2019-03-21 2021-03-02 Evan Prout Heating values of cellulosic waste
CN113493460A (zh) * 2020-03-20 2021-10-12 江苏恩华药业股份有限公司 盐酸羟考酮杂质b的制备方法
AU2021368196A1 (en) 2020-11-02 2023-06-22 Rhodes Technologies Process for purifying noroxymorphone
US11247999B1 (en) 2021-07-02 2022-02-15 Joseph DeGraw Facile conversion of morphine to normorphine

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2772270A (en) * 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (OSRAM) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (OSRAM) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
MXPA04000584A (es) 2001-07-18 2004-04-20 Euro Celtique Sa COMBINACIONES FARMACeUTICAS DE OXICODONA Y NALOXONA.
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
US20050203115A1 (en) * 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於25ppm14-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
SK286087B6 (sk) * 2004-08-18 2008-03-05 Zentiva, A. S. Spôsob prípravy oxykodonu
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US8703099B2 (en) * 2005-02-24 2014-04-22 Dr Pharma Nova, Llc Registry method and control system for DEA schedule II-V medicines
DE602006019246D1 (de) 2005-06-16 2011-02-10 Mallinckrodt Inc Synthetische route zu 14-hydroxylopiaten über 1-halogenthebain oder analoga
KR100753432B1 (ko) 2005-11-08 2007-08-31 경희대학교 산학협력단 다결정 실리콘 및 그의 결정화 방법
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
WO2008048711A1 (en) * 2006-10-17 2008-04-24 Penick Corporation Process for preparing oxymorphone
US7875719B2 (en) * 2006-12-04 2011-01-25 Cox D Phillip Process for reducing impurities in oxycodone base
EP2121699B1 (en) 2006-12-04 2012-09-19 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
GB0624880D0 (en) 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
CA2681740A1 (en) 2007-03-23 2008-10-02 Mallinckrodt Inc. Improved preparation of oxymorphone from oripavine
MX2009010931A (es) 2007-04-16 2009-10-29 Mallinckrodt Inc Reduccion novedosa de opiaceos utilizando la reaccion de transferencia catalitica de hidrogeno.
US8217204B2 (en) 2009-06-03 2012-07-10 Takasago International Corporation Catalyst for asymmetric hydrogenation
US9073934B2 (en) 2009-09-16 2015-07-07 Monash University Method for the N-demethylation of N-methyl heterocycles
EP2377866B1 (en) * 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
TWI471289B (zh) * 2010-06-11 2015-02-01 Rhodes Technologies 使三級胺進行n-脫烷反應之方法
ES2659168T3 (es) 2010-07-02 2018-03-14 Johnson Matthey Public Limited Company Proceso para la síntesis y purificación de oxicodona
JP5728084B2 (ja) 2010-07-08 2015-06-03 アルカーメス ファーマ アイルランド リミテッド 置換モルフィナンの合成のための方法
JP5780933B2 (ja) 2010-12-01 2015-09-16 高砂香料工業株式会社 光学活性メントールの製造方法
US9657029B2 (en) 2012-06-11 2017-05-23 Siegfried Generics International Ag Method of preparing oxymorphone
KR101946104B1 (ko) 2012-07-16 2019-02-08 로드스 테크놀로지즈 개선된 오피오이드 합성을 위한 방법
CN103113378B (zh) 2013-02-20 2016-04-06 北京华素制药股份有限公司 一种盐酸羟吗啡酮的合成方法
CN103433076B (zh) 2013-09-02 2015-06-24 浙江新和成股份有限公司 一种固载型不对称催化剂及其在不对称氢化反应中的应用
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
CN106164078A (zh) 2013-12-18 2016-11-23 科迪实验室公司 氧可酮盐酸盐的合成
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
MX379406B (es) 2014-01-15 2025-03-11 Rhodes Tech Proceso para la síntesis mejorada de oximorfona.
JP2017502991A (ja) 2014-01-15 2017-01-26 ローズ テクノロジーズ 改良されたオキシコドン合成のための方法

Also Published As

Publication number Publication date
CN104470928A (zh) 2015-03-25
EP2872516A1 (en) 2015-05-20
JP6236447B2 (ja) 2017-11-22
IL236710A0 (en) 2015-02-26
CA2879270A1 (en) 2014-01-23
MX2015000879A (es) 2017-02-14
CN104470928B (zh) 2017-08-11
TW201416369A (zh) 2014-05-01
CA2974010A1 (en) 2014-01-23
ES2647949T3 (es) 2017-12-27
BR112015000944A2 (pt) 2019-10-15
NZ628699A (en) 2016-05-27
EP2872516B1 (en) 2017-08-30
CA2879270C (en) 2017-09-05
US20190367526A1 (en) 2019-12-05
KR101946103B1 (ko) 2019-02-08
PH12015500089B1 (en) 2015-03-02
AU2016204926A1 (en) 2016-07-28
IL236710B (en) 2018-04-30
UA117225C2 (uk) 2018-07-10
WO2014013313A1 (en) 2014-01-23
CO7180188A2 (es) 2015-02-09
US20150315203A1 (en) 2015-11-05
KR20150029752A (ko) 2015-03-18
US10316042B2 (en) 2019-06-11
JP2015524407A (ja) 2015-08-24
US20230130617A1 (en) 2023-04-27
AU2013291725B2 (en) 2016-07-28
HK1210170A1 (en) 2016-04-15
SG11201407988UA (en) 2015-01-29
TWI643859B (zh) 2018-12-11
AU2013291725A1 (en) 2014-12-18
PH12015500089A1 (en) 2015-03-02
TWI643860B (zh) 2018-12-11
MX363610B (es) 2019-03-28
EA028092B1 (ru) 2017-10-31
TW201641502A (zh) 2016-12-01
IN2015DN01165A (OSRAM) 2015-06-26
EA201590222A1 (ru) 2015-05-29

Similar Documents

Publication Publication Date Title
AR092858A1 (es) Procedimiento para una sintesis mejorada de opioide
AR091779A1 (es) Procedimiento para la sintesis mejorada de opioides
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR091093A1 (es) Tienopirimidinas
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
AR106605A1 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR104326A1 (es) Compuestos nucleósidos 5-sustituidos
EA201891861A1 (ru) 2-(морфолин-4-ил)-1,7-нафтиридины
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
AR088000A1 (es) Derivados de pirazolquinolinona, su preparacion y su uso terapeutico
CY1120378T1 (el) Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης)
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
AR088551A1 (es) Conjugados de hidromorfona con acido benzoico, derivados de acido benzoico y acido heteroarilcarboxilico; profarmacos, metodos de preparacion y uso de los mismos
PE20160241A1 (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparacion y composiciones farmaceuticas que los contienen
RU2017132330A (ru) Соли производного хиназолина и способ их получения
AR098818A1 (es) Derivados de oxindol, preparación de los mismos y uso terapéutico de los mismos
EA201401082A1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
CL2012001322A1 (es) Compuestos derivados de piridinopiridinona, inhibidores pdgf; procedimiento de preparacion de estos; composición farmacéutica que los comprende; combinación farmacéutica; y su uso en el tratamiento del cancer, ateroesclerosis, enfermedades cardiacas, diabetes, renales, entre otras.
AR100715A1 (es) Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
AR090323A1 (es) Imidazopiridazinas sustituidas, procesos e intermediarios para su obtencion y su uso en el tratamiento de enfermedades mediadas por la quinasa mps-1
BR112016007646A2 (pt) forma cristalina anidra de cabazitaxel, uso da forma cristalina anidra de cabazitaxel, composição farmacêutica e processo para o preparo forma cristalina anidra de cabazitaxe
AR110543A1 (es) [4-(fenilsulfonil)piperazin-1-il](1h-1,2,3-triazol-4-il)metanonas

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FC Refusal